Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review

Myriam Drysdale, Daniel C. Gibbons, Moushmi Singh, Catherine Rolland, Louis Lavoie, Andrew Skingsley, Emily J. Lloyd
doi: https://doi.org/10.1101/2023.03.09.23287034

Article Information

doi 
https://doi.org/10.1101/2023.03.09.23287034
History 
  • March 10, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Myriam Drysdale1,*,
  2. Daniel C. Gibbons1,
  3. Moushmi Singh1,
  4. Catherine Rolland2,
  5. Louis Lavoie3,
  6. Andrew Skingsley4 and
  7. Emily J. Lloyd1
  1. 1Value Evidence and Outcomes, GSK, Middlesex, UK
  2. 2Evidence Synthesis, Modelling and Communications, PPD Evidera, London, UK
  3. 3Evidence Synthesis, Modelling and Communications, PPD Evidera, Montreal, Canada
  4. 4Clinical Research and Development, GSK, Middlesex, UK
  1. ↵*Corresponding author Myriam Drysdale, GSK, 980 Great West Road, Brentford, Middlesex, TW8 9GS. Email: myriam.g.drysdale{at}gsk.com
Back to top
Posted March 10, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review
Myriam Drysdale, Daniel C. Gibbons, Moushmi Singh, Catherine Rolland, Louis Lavoie, Andrew Skingsley, Emily J. Lloyd
medRxiv 2023.03.09.23287034; doi: https://doi.org/10.1101/2023.03.09.23287034
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area